A marked decrease in malaria-related deaths worldwide has been attributed to the
administration of effective antimalarials against Plasmodium falciparum, in particular …

Plasmodium falciparum malaria, an infectious disease caused by a parasitic protozoan,
claims the lives of nearly a million children each year in Africa alone and is a top public …

The widely used antimalarial combination therapy dihydroartemisinin+ piperaquine (DHA+
PPQ) has failed in Cambodia. Here, we perform a genomic analysis that reveals a rapid …

Plasmodium falciparum resistance to chloroquine, the former gold standard antimalarial
drug, is mediated primarily by mutant forms of the chloroquine resistance transporter …

Resistance to antimalarial drugs has often threatened malaria elimination efforts and
historically has led to the short-term resurgence of malaria incidences and deaths. With …

Despite intensive research extending back to the 1930s, when the first synthetic antimalarial
drugs made their appearance, the repertoire of clinically licensed formulations remains very …

Historically, the most successful molecular target for antimalarial drugs has been heme
biomineralization within the malarial parasite digestive vacuole. Heme released from …

In regions with high malaria endemicity, the withdrawal of chloroquine (CQ) as first-line
treatment of Plasmodium falciparum infections has typically led to the restoration of CQ …

Malaria represents one of the most serious threats to human health worldwide, and
preventing and curing this parasitic disease still depends predominantly on the …

Preventing and delaying the emergence of drug resistance is an essential goal of
antimalarial drug development. Monotherapy and highly mutable drug targets have each …